Are you above the legal age to view this content in your province/state?

Home / Industry News / FSD Pharma kicks off in-human study of micro-PEA in Australia

FSD Pharma kicks off in-human study of micro-PEA in Australia

FSD Pharma kicks off in-human study of micro-PEA in Australia

U.S., March 9, 2020 (Proactive)- The drug targets receptors in the endocannabinoid system and is designed to treat symptoms associated with conditions such as fibromyalgia

The study is meant to evaluate the safety, tolerability and pharmacokinetics of the drug in healthy volunteers

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) has begun a Phase 1 human study of its anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA) after winning approval from the Ethics Committee of the Alfred Hospital in Victoria, Australia. 

The drug works by targeting receptors in patients’ endocannabinoid system and is designed to treat the symptoms associated with conditions such as fibromyalgia. The new Phase 1 study is meant to evaluate the safety, tolerability and pharmacokinetics of the drug in healthy volunteers.

“The initiation of this Phase 1 in-human safety and tolerability clinical study of ultra-micronized formulation of PEA is a ground-breaking milestone for our company as we stride forward to find novel anti-inflammatory treatment outcomes for patients by targeting the CB2 receptors of the endocannabinoid system,” CEO Raza Bokhari said in a statement.

Bokhari gave credit to the head of the company’s BioSciences division.

“I must congratulate Dr. Edward Brennan, President of FSD Pharma’s BioSciences Division, and his very qualified team on delivering this milestone on schedule,” Bokhari said. “Dr. Brennan’s decades of experience in drug development is very noteworthy, and I share his confidence that this Phase 1 in-human study based on US FDA-approved guidelines will produce favorable data. 

“The study would validate considerable scientific literature already published, over the years, in the European Union, that claims safety and tolerability of micro-PEA, which is being dispensed in Italy and Spain as a prescription-based medical food supplement since 2004.”

FSD Pharma is focused on the research and development of cannabinoid-based treatments for several central nervous system disorders, including fibromyalgia, and irritable bowel syndrome.

Headquartered at the former Kraft plant in Cobourg, Ontario, with large expansion potential, FSD also grows medical-grade cannabis at its 25,000 square foot facility in Ontario.

Through its wholly-owned subsidiary FV Pharma Inc, the group is a licensed producer under Canada’s Cannabis Act, having received its cultivation license in October 2017 and its sale for medical purposes license in April 2019.

Disclaimer

Investment Value Finders specializes in providing opinions and information on stocks to individuals who wish to receive them. Our reports are construed for information purposes solely and are distributed free of charge to individuals who wish to receive them.


Investment Value Finders does not promote, condone or advocate licit or illicit drug use. Investment Value Finders cannot be held responsible for materials or contests posted on its website pages, or pages to which we provide links, which promote, condone or advocate licit or illicit drug use or illegal activities.


DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE. We are not registered as a securities broker-dealer or an investment adviser. We are neither licensed nor qualified to provide investment advice.


Investment Value Finders occasionally receives direct compensation for hosting links (or other* advertisements) to third party content that may be subject to disclaimer pursuant to Section 17(b) of the Securities Act of 1933. For those instances where the link text contains company or stock-specific mention, we provide the following list of compensation received in order to ensure full disclosure and transparency.


Investment Value Finders is intended for those 21+ years of age only!

Check Also

CBD crystals are coming to Canada

CBD crystals are coming to Canada

This story originally appeared on The Growth Op. Ontario’s MediPharm Labs Corp. has launched a new …